August 23, 2021
Video
Cheryl Larson, president and CEO of Midwest Business Group on Health, discusses current efforts to manage drug spend and the high cost of specialty drugs on the market.
July 29, 2021
Article
The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.
Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.
July 26, 2021
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
July 15, 2021
The pipeline for biosimilar products in the United States includes at least 26 candidates in phase 3 trials for 13 reference therapies.
May 11, 2021
Bhavesh Shah, RPh, BCOP; Brandon Dyson, PharmD, BCOP, BCPS; Ryan Haumschild, PharmD, MS, MBA; and Tim Peterson, PharmD, BCOP, provide advice and strategies for adopting biosimilars into clinical practice.
May 06, 2021
The impact of the COVID-19 pandemic on the rate of biosimilar adoption in clinical practice, updates to NCCN guideline recommendations, and financial implications associated with the utilization of biosimilars.
May 04, 2021
The influence of provider buy-in for getting a biosimilar onto formulary and the role of providers in the incorporation of biosimilars are discussed.
April 29, 2021
Overcoming barriers for payer coverage of biosimilars as well as considerations for carrying costs are discussed.
April 28, 2021
Brandon Dyson, PharmD, BCOP, BCPS, shares his approach to switching a patient already on biologic therapy to a biosimilar, and panelists discuss the importance of education regarding the extrapolation of indications for biosimilars.
